| Description | Ridazolol is a vasodilating and cardioselective beta adrenergic blocker. |
| Synonyms | Ridazololum |
| molecular weight | 373.23 |
| Molecular formula | C15H18Cl2N4O3 |
| CAS | 83395-21-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 35.4 mg/mL (100 mM), Sonication and heating are recommended. |
| References | 1. Unger P, Berkenboom G, Fontaine J. Study of ridazolol on isolated canine and human coronary arteries. Cardiovasc Drugs Ther. 1989 Jun;3(3):459-64. PubMed PMID: 2577285. 2. Fach WA, Starke E, Becker HJ. [Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease]. Z Kardiol. 1992 Jun;81(6):320-5. German. PubMed PMID: 1353933. 3. Haerer W, Henze E, Stauch M. [The effect of a combination of ridazolol and molsidomine on hemodynamics and left ventricular function in dilated cardiomyopathy]. Arzneimittelforschung. 1989 Jun;39(6):714-6. German. PubMed PMID: 2570582. 4. Rommel T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm Gen Sect. 1994;95(1):39-48. PubMed PMID: 7857585. |